The European specialty pharma M&A landscape is undergoing significant transformations, with private equity firms facing new and unprecedented challenges. This white paper examines the current state of private equity within the sector, identifying the key obstacles and trends reshaping investment strategies.
Private Equity’s Path in European Specialty Pharma M&A
Download Request